Authorized, Denied, Delayed: How Insurance Paperwork Decides Who Sees a Dermatologist

A patient in Boston with a suspicious mole may see a board-certified dermatologist within two weeks. A patient with the same lesion in rural Mississippi may wait three months, drive two hours, and still face a bill that surprises them. The difference is rarely the diagnosis. More often, it is the insurance card in the patient's wallet — and the paperwork standing between that card and an appointment.

The Geography of Access

Dermatologist density varies dramatically across the country. Metropolitan areas in the Northeast and on the West Coast are well supplied with specialists, while large swaths of the rural South, Midwest, and Mountain West are designated Health Professional Shortage Areas. A patient's zip code frequently determines how far they must travel, how long they must wait, and whether a dermatologist is realistically within reach at all.

Insurance compounds this uneven landscape. Medicaid programs, which are administered state by state, differ widely in which dermatologic services they cover, which medications they approve, and how much they reimburse physicians — a factor that influences whether practices can afford to accept those patients at all.

Prior Authorization: The Hidden Waiting Room

Few administrative requirements shape dermatologic care more than prior authorization. Before prescribing many biologic medications for psoriasis, eczema, or chronic urticaria, dermatologists must first submit documentation demonstrating that cheaper alternatives were tried and failed — even when clinical guidelines suggest the biologic is appropriate from the outset.

The consequences are measurable. Studies of specialty practices, including dermatology, have found that a substantial share of prior authorization requests are ultimately approved after appeal, yet the process consumes staff hours, delays treatment by weeks, and sometimes leads patients to abandon therapy altogether. For a condition like moderate-to-severe psoriasis, a two-month delay is not an inconvenience; it is months of continued itching, pain, and diminished quality of life.

Telehealth Rules: A Patchwork That Shifts

The pandemic-era expansion of telemedicine proved that much of dermatology — a visual specialty — can be delivered remotely. But as emergency declarations ended, states and insurers rewrote their telehealth rules independently. Some states now impose in-person visit requirements before certain prescriptions can be issued. Others restrict which providers can bill across state lines. A patient in one state may resolve a persistent rash over a video visit covered by their plan; a patient across the river may be required to appear in person, adding travel costs and lost wages to the bill.

What Patients Can Do

Navigating this system is frustrating, but patients are not powerless. Dermatologists and patient advocates recommend several concrete steps:

• Request the denial reason in writing. Insurers are required to explain coverage decisions, and the stated reason often reveals the fastest path to reversal.
• Ask your dermatologist to submit a letter of medical necessity. Peer-to-peer reviews, in which the physician speaks directly with the insurer's medical director, overturn denials at meaningful rates.
• File a formal appeal on time. Most plans allow internal appeals within 180 days, and Medicare and ACA-compliant plans guarantee an external review by an independent party.
• Check your state's Medicaid formulary and telehealth policies if you are covered by public insurance — coverage details vary more than most patients realize.
• Ask about manufacturer patient-assistance programs for brand-name dermatologic medications, which can reduce or eliminate out-of-pocket costs for eligible patients.
• Explore community options. Federally Qualified Health Centers, dermatology residency clinics at academic medical centers, and nonprofit screening events offer lower-cost pathways to care.

A System Worth Questioning

Board-certified dermatologists train for years to distinguish a harmless lesion from a dangerous one and to restore quality of life to patients with chronic inflammatory disease. Yet the growing share of clinical time spent on administrative appeals represents hours not spent on patient care.

Professional societies, including the American Academy of Dermatology, continue to advocate for streamlined authorization processes and equitable coverage. Until those reforms arrive, the most powerful tool available to patients is informed persistence: understand your plan, document your care, and appeal denials — because the data show that appeals, more often than not, succeed.